Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zelenirstat (Primary)
Indications Advanced breast cancer; Appendiceal cancer; B-cell lymphoma; Bladder cancer; Burkitt's lymphoma; Colon cancer; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors PACYLEX PHARMACEUTICALS

17 Apr 2025 The protocol has been amended to change in Allocation as Randomized with increase in drug arm size and change in primary endpoint timeframe.
17 Apr 2025 Status changed from recruiting to completed.
04 Jun 2024 Final results of dose escalation phase (n=29) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com